Target molecules for anti-angiogenic therapy: from basic research to clinical trials (Q33912018)

30 July 2017

1 reference

title

Target molecules for anti-angiogenic therapy: from basic research to clinical trials (English)

1 reference

30 July 2017

angiogenesis inhibitor

1 reference

Hagedorn M

1

1 reference

PubMed ID

10799835

30 July 2017

Bikfalvi A

series ordinal

2

1 reference

PubMed ID

10799835

30 July 2017

language of work or name

1 reference

1 May 2000

1 reference

Critical Reviews in Oncology Hematology

30 July 2017

1 reference

30 July 2017

34

1 reference

30 July 2017

2

1 reference

30 July 2017

89-110

1 reference

Angiogenesis in cancer, vascular, rheumatoid and other disease

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Mechanisms of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Signaling vascular morphogenesis and maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiogenesis and vasculogenesis in treatment of cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Vascular endothelial growth factor is a secreted angiogenic mitogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Vascular permeability factor, an endothelial cell mitogen related to PDGF

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Vascular endothelial growth factor B, a novel growth factor for endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Molecular cloning of a novel vascular endothelial growth factor, VEGF-D

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Molecular cloning and characterization of mouse TIE and TEK receptor tyrosine kinase genes and their expression in hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiopoietins 3 and 4: diverging gene counterparts in mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Heparin Affinity: Purification of a Tumor-Derived Capillary Endothelial Cell Growth Factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Basic fibroblast growth factor induces angiogenesis in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Adenovirus-mediated expression of the secreted form of basic fibroblast growth factor (FGF-2) induces cellular proliferation and angiogenesis in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

The functional role of the ELR motif in CXC chemokine-mediated angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

In vitro and in vivo systems to assess role of C-X-C chemokines in regulation of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Protamine is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Differences in binding of platelet factor 4 to vascular endothelium in vivo and endothelial cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Inhibition of angiogenesis in vivo by interleukin 12.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

IL-12 regulates VEGF and MMPs in a murine breast cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Organogenesis and angiogenin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Limited proteolysis of angiogenin by elastase is regulated by plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Actin is a binding protein for angiogenin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

A putative angiogenin receptor in angiogenin-responsive human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Inhibition of human angiogenin by DNA aptamers: nuclear colocalization of an angiogenin-inhibitor complex.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Neomycin inhibits angiogenin-induced angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Expression of thrombospondin-1 in ischemia-induced retinal neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during n

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Alpha v integrins as receptors for tumor targeting by circulating ligands.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Complex role of matrix metalloproteinases in angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiogenesis inhibited by drinking tea.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiogenesis in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Histotypic angiogenesis in vitro: Light microscopic, ultrastructural, and radioautographic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Tumor Growth and Neovascularization: An Experimental Model Using the Rabbit Cornea 2

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiogenesis in the mouse cornea

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Orthotopic human melanoma xenograft model systems for studies of tumour angiogenesis, pathophysiology, treatment sensitivity and metastatic pattern

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Fibrinolysis and angiogenesis in wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Avascular and vascular phases of tumour growth in the chick embryo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

A simple procedure for the long-term cultivation of chicken embryos

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Increased vascularization in mice overexpressing angiopoietin-1

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Cardiovascular failure in mouse embryos deficient in VEGF receptor-3

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Tumor targeting with a selective gelatinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Photodynamic therapy in the management of metastatic cutaneous adenocarcinomas: case reports from phase 1/2 studies using tin ethyl etiopurpurin (SnET2).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Clinical trials of anti-vascular agent group B Streptococcus toxin (CM101)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Ovarian cancer cell invasion is inhibited by paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Successful treatment of infantile hemangiomas with interferon-alpha-2b

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900056-1

7 January 2021

10.1016/S1040-8428(00)00056-1

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10799835